drugset / Trial / NCT01887418

Pharmacokinetic Study of Testosterone Enanthate

NCT01887418

Phase 1/2 Completed 39 enrolled Antares Pharma Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.

Timeline

Start
2013-09
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Enanthate Small molecule 50 mg Subcutaneous
Subject Testosterone Enanthate Small molecule 100 mg Subcutaneous
Subject Testosterone Enanthate Small molecule 200 mg Subcutaneous

Indications